Table 2 Intraoperative, post-operative and oncological outcomes
| Â | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|---|---|---|---|---|---|
Operative date | 23-Nov-05 | 11-June-10 | 08-Apr-15 | 06-Dec-18 | 05-Mar-20 |
Type of RP | ORP | LRP | RS-RALRP | RALRP | RALRP |
Nerve sparing | No | No | No | No | Unilateral |
Operative time (min) | 365 | 210 | 210 | 190 | 210 |
EBL (mLs) | 630 | 300 | 250 | 150 | 100 |
Prostate specimen weight (g) | 34.8 | 40 | 24 | 23.5 | 30 |
Perioperative complication | None | None | None | None | None |
Complication by Clavien-Dindo classification | 2 | 2 | 1 | 1 | 1 |
Complication | Blood transfusion and postoperative fever | Blood transfusion and postoperative fever | Â | Â | Â |
LOS (days) | 13 | 6 | 8 | 5 | 7 |
Pathological Gleason score | 4 + 5 | 3 + 3 | 4 + 3 | 4 + 5 | 3 + 4 |
Pathological T stage | T3b | T2a | T2c | T3b | T2a |
Marginal status | Positive | Negative | Positive | Positive | Negative |
Follow-up period (months) | 129 | 47 | 63 | 31 | 6 |
Creatinine (mg/dl) | |||||
Preoperative | 1.3 | 1 | 1.41 | 0.66 | 1.11 |
1Â day postoperative | 1.2 | 0.8 | 1.38 | 0.57 | 0.87 |
3Â days postoperative | 1.12 | Not measured | 0.88 | 0.58 | 0.79 |
7Â days postoperative | 1.25 | Discharged | 1.06 | Discharged | 0.78 |
The last available Cr | 1.6 Year 2016 | 1.28 Year 2014 | 1.74 Year 2020 | 0.65 Year 2020 | 1.05 May-20 |
Survival/oncological status | PSA persistence, on ADT until death in 2016 due to progressive allograft dysfunction with uremia | Recurrence free until death in 2014 due to sigmoid colon carcinoma with gut obstruction and septic shock | PSA recurrence at 13 months. Then on ADT, PSA < 0.003 at the follow up on 9 June 2020 | PSA persistence, on ADT. PSA of 0.85 at the follow-up on 25 May 2020 | Recurrence free at the follow-up on May 2020 |
Return of urinary continence after surgery | 1Â year | 1Â year | 1Â month | 6Â months | 6Â months |